Medication in acute myocardial infarction -- does it do as much harm as good?

Related Experiment Video

Updated: Oct 13, 2026

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

R H Falk

    Medical Hypotheses
    |October 1, 1979
    PubMed

    Insights

    Coronary care units may not reduce acute myocardial infarction mortality. Detrimental effects, like medication side-effects, might offset benefits, potentially increasing non-arrhythmic deaths.

    Area of Science:

    • Cardiology
    • Critical Care Medicine

    Background:

    • Coronary care units (CCUs) have shown success in preventing deaths from ventricular fibrillation.
    • However, overall mortality from acute myocardial infarction (AMI) remains unchanged whether patients are treated at home or in CCUs.

    Purpose of the Study:

    • To investigate the paradox of unchanged AMI mortality despite CCU benefits.
    • To examine potential detrimental effects of CCUs that may counteract their advantages.

    Main Methods:

    • Review of existing evidence on CCU outcomes and patient treatment.
    • Analysis of factors contributing to AMI mortality in different treatment settings.

    Main Results:

    • No significant difference in mortality rates for acute myocardial infarction between home care and CCU care.
    • Potential for CCUs to have detrimental effects that balance their beneficial impact.

    Conclusions:

    • The effectiveness of CCUs in reducing overall AMI mortality is questionable.
    • Antiarrhythmic medications used in CCUs may increase mortality due to non-arrhythmic side-effects, contributing to the observed paradox.

    More Related Videos

    Myocardial Infarction and Functional Outcome Assessment in Pigs12:03

    Myocardial Infarction and Functional Outcome Assessment in Pigs

    Published on: April 25, 2014

    Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy07:40

    Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

    Published on: May 26, 2023

    Related Concept Videos

    Antianginal Drugs: Nitrates and β-Blockers01:16

    Antianginal Drugs: Nitrates and β-Blockers

    In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
    Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
    Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

    Antianginal Drugs: Calcium Channel Blockers and Ranolazine

    Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
    CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
    Myocarditis III: Medical Management01:14

    Myocarditis III: Medical Management

    Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
    Coronary Artery Disease V: Interprofessional Care01:27

    Coronary Artery Disease V: Interprofessional Care

    Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
    Acute Coronary Syndrome I: Introduction01:30

    Acute Coronary Syndrome I: Introduction

    Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
    Acute Coronary Syndrome IV: Interprofessional Care01:28

    Acute Coronary Syndrome IV: Interprofessional Care

    IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...